Figure 6

miR-19a reverses gefitinib resistance in NSCLC cells by targeting c-Met (A). A549 cells were transfected with c-Met siRNA (si-Met), and the c-Met protein level was detected with a western blot (left); the cells were transfected with si-Met and treated with gefitinib, and cell viability (right) and apoptosis rate (center) were measured after 48 h; (B) A549 cells were transfected with Inh-19a or co-transfected with Inh-19a and si-Met and treated with different doses of gefitinib for 72 h before measuring cell viability by CCK8; (C) The cells were transfected with Inh-19a or co-transfected with Inh-19a and si-Met and treated with 1 µM gefitinib before examining apoptosis using the Annexin V-PI assay (mean ± sd, n = 3, **p < 0.01); (D) The cells were transfected with Inh-19a or co-transfected with Inh-19a and si-Met; the cell morphology is shown; (E) The cells were transfected with Inh-19a or co-transfected with Inh-19a and si-Met, and the protein levels of c-Met and its downstream pathway effectors were detected in each group.